Treatment with a TGF-β receptor inhibitor, LY2109761, decreased secreted CTGF; and reduced hepatocellular carcinoma growth and dissemination by inhibiting CAF proliferation [102]. Here, CCN2 is linked to hepatocellular carcinoma.